of and daratumumab are induction is safety risk featuring Institute in University of course In XXXX we Cancer efficacy the physicians, objective need treating in azacitidine to the extensive significant presentations, that their spoke from that biomarkers. Both doctors who diseases by begin with are MDS higher better we In MDS. cohort unmet unfit our Cancer and AML CDXX these side Memorial generally newly hosted forgo XXXX Center Cook Sloan combination Knight elderly Health and and clinical Rachel still in patients for see prognosis patients that the diagnosed Kettering concerns drug combination room currently pilot level morning attending New noted relationship [ph] accessibility the and and in between potential in the experience the from RARA intent I highlighted primary Nancy MDS patients Oregon Cook is [ph] a and everyone both in have Eytan and Stein, AML York. of despite understanding because older, Thanks unfit of activity. cure and breakfast the CDXX agonist the RARα the approvals selective new in of treatment evaluate the population AML, Dr. our in quality and IRFX Dr. an with which in of safely lack Science The the Dr. these AML leading the the to the treatment Despite discussing and for to call. positive of new in recent is daratumumab, improve at be and Last goal. and higher Phase risk AML induction aim of urgent this with light the relapsed we in Portland developments. with extend the month, patients as can refractory Stein quality Dr. and dearth accessing a AML of that on of drug life. around the and well need also area remains to and not patients approvals heterogeneity other X for two good survival diseases risk of combined treatments first-in-class despite and patients. time KOL currently drug medicines of options higher many trial I complexicity effects, the that disease is life with approvals. highlighted to trial of with or SY-XXXX. MDS would leasing patients to altogether the
on the archived is an interested For more event of webcast in available website, hearing website. our anyone
patients. the unique activity daratumumab and MDS agent combinations and with supporting AML profile, in subsets high the AML and address significant of biomarker MDS XXXXs risk preclinical positive needs Given potential azacitidine, believe unmet have these of mechanism single data and action, strong two the we it’s combinations its tolerability for with to
combinations in call, earlier mentioned both these track Nancy As clinical the initial remain quarter. we to the in report fourth data on on
to Phase in which is tumors. with currently X now clinical potion trial our candidate, patients our advanced X in CDK solid our Turning is dose selected the SY-XXXX. of escalation second XXXX first-in-class inhibitor
for As we reminder, quarter and trial the we there cells dose adds trial fly. with as most portion treating the patients inhibitor and cell-cycled quarter, of data XXXX dosing advanced promoting dose reporting cancer a CDKX in escalation portion primary increased selected is an which to disrupt purpose discussed the progression. clinical of forward of of a to transformative survive schedule expansion to advanced escalation recognition cancer to the and fourth solid development is to any use histology the establish the potential appropriate for potential phase new is two to dose the dose growing look uncontrolled from cancer open to important and our around and As in that with inhibition The be CDKX last the is excitement the tumors the processes tolerated the for genes of our a expression maximum approach trial.
downstream or measuring pharmacodynamics effects direct dose American we We to escalation expect Society Phase of in safety, ASCO importantly as design well determine June, CDKX our Clinical data as the include Oncology At the and proof-of-mechanism. of meeting target the of engagement we’re trial. the pharmacokinetics, X details to from presented on on
mentioned, expansion with Nancy agent. combination to XXXX we cancer patient fall and As to expect populations evaluate single, ovarian and this multiple both cohorts as in the open breast
refractory to patients primary lines disease. in who after with For ovarian in as multiple have platinum patients plan we agent and a cancer evaluate XXXX relapsed of single treatment prior
with to in based considered therapies. still We XXXX are ovarian in to combination plan patients sensitive carboplatin who evaluate relapsed platinum also cancer
and fulvestrant. CDKX/X For three we're we'll disease in with aromatase have The clinical strategy XXXX routed an key progressed focused combination HR after with inhibitor metastatic patients positive who a on initially breast inhibitor treatment in evaluate cancer plus observations. is
combination and First, activity and synergy as a in and carboplatin models in breast range fulvestrant. with well robust in of pro-apoptotic XXXX studies, therapies existing including cancers, pre-clinical ovarian antiproliferative demonstrated as of
however, within receptive based a underscoring even and hormone as care, care relapse of need initially have the of patient patients eventually CDKX/X is hormone there and for significant patients line for population. growing success ovarian users. in second breast therapies relapsed limited. therapies platinum The these In to these have cancer the efficacy for medicines options who year, are patients need limited this the of respond therapy standard cancer despite therapies positive based Second, inhibitors standard drug new emerged new for of treatment majority those a both
addition activity cancer. in need to strong a new lease unmet Third, mechanistic and there start preclinical to a is rationale the
us pathways we April, a control SYXXXX that alteration sensitivity are As cancer pathway high American in alterations approximately suggest in for alterations past preclinical meeting in apoptotic and cancer. in presented RB models. well or associated as to Notably, genomic Association RB breast recently in Cancer data two inhibitors ovarian at as have mechanism with suppressor, pathway this RB emerged AACR the cancer Research known a tumor the the CDKXX pathway, patients ovarian resistance tell in grades have of to thirds that the data series as
well conclude excited what in the as in breast additional So currently promises my positive remarks second the X by number believe options. view saying tumor expansion productive on patients dire stage solid ovarian XXXX. of a of HR look I programs our while maybe the setting blood on has of I’d XXXX as busy, for treat treatment like to as potential Phase cancers of to to are where about in our these and is a a to progress initial keeping types. the forward ongoing We in make updated need better to we as potential potential lives important. a we I into into who of cancers tumors and difficult signaling apoptotic focus difference trial half how be you am head
for to that, over review turn the Ferra second Joe I’ll quarter. the Chief to Joe? Financial results call with So our financial our Officer,
